Business
Certara Appoints Jon Resnick as Chief Executive Officer
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step
About this update from Certara, Inc.
[{"type":"text","content":"Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara’s Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a global technology-enabled, data and analytics and services business that helps life sciences organizations develop and commercialize therapies. Since 2019, he has served as the President of the United States and Canada regional business, with overall management responsibility for the region’s commercial business. Prior to this role and immediately following the merger of IMS Health and Quintiles, Resnick served as President of IQVIA’s Real World Solutions business. Before the merger, Resnick was the Vice President and General Manager for IMS Health’s Real-World Solutions business and had various positions in IQVIA’s US and EMEA consulting and services organization. “We are excited to welcome Jon to Certara,” said James E. Cashman III, Chairman of the Board of Directors. “He brings a proven track record of building and scaling market leaders, advancing technological innovation in healthcare and life sciences and fostering collaborative teams. We are confident that his leadership will help propel Certara to its next phase of growth and realize the full potential of model-informed drug development in accelerating medicines to patients.” \"I am thrilled to join Certara, a market-leading strategically important company at the forefront of innovation in drug discovery and development,\" said Resnick. “Certara's suite of AI, data and simulation technologies, backed by a team of world-class experts, is uniquely positioned to drive long-term growth, while helping clients reduce risk, accelerate timelines and transform how medicines reach patients. I look forward to leading this talented team and helping our clients reach their goals.” Prior to joining IQVIA...